Validation Data Gallery
Tested Applications
Recommended dilution
Application | Dilution |
---|---|
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
CL594-66015 targets RBBP9 in applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Mouse / IgG2b |
Class | Monoclonal |
Type | Antibody |
Immunogen | RBBP9 fusion protein Ag17864 相同性解析による交差性が予測される生物種 |
Full Name | retinoblastoma binding protein 9 |
Calculated molecular weight | 186 aa, 21 kDa |
Observed molecular weight | 22 kDa |
GenBank accession number | BC015938 |
Gene Symbol | RBBP9 |
Gene ID (NCBI) | 10741 |
Conjugate | CoraLite®594 Fluorescent Dye |
Excitation/Emission maxima wavelengths | 588 nm / 604 nm |
Form | Liquid |
Purification Method | Protein A purification |
UNIPROT ID | O75884 |
Storage Buffer | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
RBBP9, also named as BOG, RBBP10, RBBP-9, RBBP-10 and Protein BOG, belongs to the RBBP9 family. It may play a role in the transformation process due to its capacity to confer resistance to the growth-inhibitory effects of TGF-β1 through interaction with retinoblastoma and the subsequent displacement of E2F-1. RBBP9 is a tumor-associated serine hydrolase activity required for pancreatic neoplasia. It mediates suppression of TGF-β signaling is required for E-cadherin expression as loss of the serine hydrolase activity leads to a reduction in E-cadherin levels and a concomitant decrease in the integrity of tumor cell-cell junctions..RBBP9 protein levels were equivalent in paired primary tumor and nonneoplastic specimens(PMID:20080647)